Your browser doesn't support javascript.
loading
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi, Alireza; Caramuta, Stefano; Seashore-Ludlow, Brinton; Boström, Johan; Robinson, Jonathan L; Edfors, Fredrik; Tuominen, Rainer; Kemper, Kristel; Krijgsman, Oscar; Peeper, Daniel S; Nielsen, Jens; Hansson, Johan; Egyhazi Brage, Suzanne; Altun, Mikael; Uhlen, Mathias; Maddalo, Gianluca.
Affiliation
  • Azimi A; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Caramuta S; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Seashore-Ludlow B; Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Boström J; Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Robinson JL; Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, Sweden.
  • Edfors F; Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Tuominen R; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Kemper K; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Krijgsman O; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Peeper DS; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nielsen J; Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, Sweden.
  • Hansson J; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Egyhazi Brage S; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Altun M; Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Uhlen M; Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Maddalo G; Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden gianluca.maddalo@scilifelab.se.
Mol Syst Biol ; 14(3): e7858, 2018 03 05.
Article in En | MEDLINE | ID: mdl-29507054
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oximes / Phthalic Acids / Drug Resistance, Neoplasm / Cyclin-Dependent Kinase 2 / Microphthalmia-Associated Transcription Factor / Azabicyclo Compounds / Imidazoles / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Syst Biol Journal subject: BIOLOGIA MOLECULAR / BIOTECNOLOGIA Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oximes / Phthalic Acids / Drug Resistance, Neoplasm / Cyclin-Dependent Kinase 2 / Microphthalmia-Associated Transcription Factor / Azabicyclo Compounds / Imidazoles / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Syst Biol Journal subject: BIOLOGIA MOLECULAR / BIOTECNOLOGIA Year: 2018 Document type: Article Affiliation country: Country of publication: